Strontium ranelate is the active agent of a medicine developed for postmenopausal osteoporosis treatment. According to the literature, there are no reports of analytical methods for the determination of strontium in this matrix. Low doses of strontium have important pharmacological effects on bone; however, high doses of this element may cause toxic effects as skeletal abnormalities, rickets and defective bone mineralization. Because of this, it is important to quantify strontium in new pharmaceutical formulation. Therefore, the current study aims to develop and apply a classical analytical method based on the oxidation-reduction volumetry (specifically permanganometry), for simple, fast and low cost quantification. In addition, quality drug control, specifically the dosing test, which quantifies the amount of strontium ranelate in the medicine, may be indirectly carried out using the suggested method for determining strontium. The method was validated according to the following analytical analytical parameters: linearity, limit of quantification, limit of detection, precision, accuracy and robustness.